TOP TEN perturbations for 38854_at (Homo sapiens)
Organism: Homo sapiens
Gene: 38854_at
Selected probe(set): 206003_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array
Expression of 38854_at (206003_at) across 6674 perturbations tested by GENEVESTIGATOR:
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.121131Number of Samples:2 / 13
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; serous cystadenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary serous cystadenocarcinoma, NOS of the ovary (subcutaneously implanted). |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-3.0771189Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; clear cell adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary clear cell adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
TNF-ɑ; IL-1b; IL-6; PGE2 study 1 / control antibody treated immature dendritic cell sample
Relative Expression (log2-ratio):2.7699957Number of Samples:4 / 5
Experimental | TNF-ɑ; IL-1b; IL-6; PGE2 study 1 |
Immature dendritic cells (DCs) treated with inflammatory cytokine cocktail (10 ng/ml IL-1b, 1,000 U/ml IL-6, 10 ng/ml TNF-ɑ, 1μg/ml prostaglandin E2) for 24 h. | |
Control | control antibody treated immature dendritic cell sample |
Immature dendritic cells (DCs) treated with isotype control antibody (10 - 20μg/ml mouse IgG1 isotype) for 24 h. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary)
Relative Expression (log2-ratio):-2.4939222Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; adenocarcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary adenocarcinoma, NOS of the ovary (subcutaneously implanted). |
echinomycin study 1 / deferoxamine study 5
Relative Expression (log2-ratio):-2.2392673Number of Samples:3 / 3
Experimental | echinomycin study 1 |
Echinomycin (100nM; 2h) treated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code:--- | |
Control | deferoxamine study 5 |
Untreated human astroglioma (U251) cells, stimulated with deferoxamine (DFO; 300mM; 16h). ATC code: |
F. tularensis study 1 (novicida) / uninfected peripheral blood monocyte sample
Relative Expression (log2-ratio):2.137704Number of Samples:4 / 6
Experimental | F. tularensis study 1 (novicida) |
Peripheral blood monocytes infected with the Francisella tularensis subspecies novicida isolate U112 (100 MOI) for 24 hours. | |
Control | uninfected peripheral blood monocyte sample |
Peripheral blood monocytes uninfected. |
ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) / ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary)
Relative Expression (log2-ratio):-2.0221605Number of Samples:2 / 2
Experimental | ovarian tumor study 30 (PDX; transitional cell carcinoma, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary transitional cell carcinoma, NOS of the ovary (subcutaneously implanted). | |
Control | ovarian tumor study 30 (PDX; mixed tumor, malignant, NOS; primary) |
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary mixed tumor, malignant, NOS of the ovary (subcutaneously implanted). |
E. coli study 2 / unstimulated, normal monocyte-derived macrophage sample
Relative Expression (log2-ratio):1.9849567Number of Samples:5 / 7
Experimental | E. coli study 2 |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours with 2.5 × 105 heat-killed E. coli. | |
Control | unstimulated, normal monocyte-derived macrophage sample |
Monocyte-derived macrophage samples derived from healthy control subjects cultured for 4 hours unstimulated. |
Huntington's disease study 11 / normal dermal fibroblast cell sample
Relative Expression (log2-ratio):1.9393435Number of Samples:6 / 3
Experimental | Huntington's disease study 11 |
Primary dermal fibroblast cell samples isolated from male subjects with Huntington's disease (HD). Subjects with inflammatory or infective conditions were excluded. One sample of HD fibroblast cells (ID:GM04799) was purchased from the Coriell Cell Repository. Cells were cultured in MEM medium supplemented with 10% FBS and antibiotics. Cells were used at passage 8-10 and harvested by trypsin treatment. | |
Control | normal dermal fibroblast cell sample |
Primary dermal fibroblast cell samples isolated from healthy male subjects. Cells were cultured in MEM medium supplemented with 10% FBS and antibiotics. Cells were used at passage 8-10 and harvested by trypsin treatment. |
VTX-2337 study 1 / untreated monocyte sample
Relative Expression (log2-ratio):1.9277134Number of Samples:3 / 3
Experimental | VTX-2337 study 1 |
Peripheral blood monocytes isolated from healthy donors. Cells were treated overnight with 1uM VTX-2337 drug, which represents a TLR8 (Toll-like receptor 8) agonist with potential immunostimulating and antineoplastic activities. | |
Control | untreated monocyte sample |
Peripheral blood monocytes isolated from healthy donors. |